Free Trial

Nuvectis Pharma (NVCT) News Today

Nuvectis Pharma logo
$9.25 -0.37 (-3.85%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$9.25 0.00 (0.00%)
As of 05/2/2025 07:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Nuvectis Pharma, Inc. stock logo
Marshall Wace LLP Acquires 81,757 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT)
Marshall Wace LLP increased its holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) by 191.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,571 shares of the company's stock a
Nuvectis Pharma, Inc. stock logo
Nuvectis Pharma (NASDAQ:NVCT) Earns "Buy" Rating from HC Wainwright
HC Wainwright reiterated a "buy" rating and set a $15.00 price target (up previously from $11.00) on shares of Nuvectis Pharma in a report on Wednesday.
Nuvectis Pharma, Inc. stock logo
Nuvectis Pharma (NVCT) Projected to Post Earnings on Tuesday
Nuvectis Pharma (NASDAQ:NVCT) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-nuvectis-pharma-inc-stock/)
Nuvectis Pharma, Inc. stock logo
Nuvectis Pharma (NASDAQ:NVCT) Trading 5.3% Higher - Here's What Happened
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 5.3% - Should You Buy?
Nuvectis Pharma, Inc. stock logo
Maxim Group Begins Coverage on Nuvectis Pharma (NASDAQ:NVCT)
Maxim Group initiated coverage on Nuvectis Pharma in a research report on Wednesday. They set a "buy" rating and a $17.00 price target on the stock.
Nuvectis Pharma initiated with a Buy at Maxim
Nuvectis Pharma, Inc. stock logo
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Short Interest Update
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 1,340,000 shares, a decline of 14.1% from the February 13th total of 1,560,000 shares. Based on an average daily volume of 107,000 shares, the short-interest ratio is currently 12.5 days. Currently, 11.1% of the shares of the company are sold short.
Nuvectis Pharma, Inc. stock logo
Laidlaw Begins Coverage on Nuvectis Pharma (NASDAQ:NVCT)
Laidlaw initiated coverage on shares of Nuvectis Pharma in a research report on Monday. They set a "buy" rating and a $19.00 price target for the company.
Nuvectis Pharma initiated with a Buy at Laidlaw
Nuvectis Pharma, Inc. stock logo
Analysts Set Expectations for Nuvectis Pharma Q1 Earnings
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Nuvectis Pharma in a note issued to investors on Tuesday, February 25th. HC Wainwright analyst J. Pantginis expects that the company will post earni
Nuvectis Pharma, Inc. stock logo
Roth Capital Forecasts Reduced Earnings for Nuvectis Pharma
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Equities researchers at Roth Capital lowered their Q1 2025 earnings per share estimates for Nuvectis Pharma in a research report issued on Tuesday, February 25th. Roth Capital analyst J. Aschoff now anticipates that the company will post earning
Nuvectis Pharma, Inc. stock logo
FY2028 EPS Forecast for Nuvectis Pharma Reduced by Analyst
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) - Equities research analysts at Roth Capital lowered their FY2028 earnings per share (EPS) estimates for shares of Nuvectis Pharma in a research note issued to investors on Tuesday, February 25th. Roth Capital analyst J. Aschoff now anticipates th
Nuvectis Pharma price target lowered to $11 from $21 at H.C. Wainwright
Nuvectis Pharma, Inc. stock logo
HC Wainwright Cuts Nuvectis Pharma (NASDAQ:NVCT) Price Target to $11.00
HC Wainwright cut their price objective on shares of Nuvectis Pharma from $21.00 to $11.00 and set a "buy" rating on the stock in a report on Tuesday.
Nuvectis Pharma, Inc. stock logo
Nuvectis Pharma (NASDAQ:NVCT) Issues Earnings Results
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.08).
Nuvectis Pharma reports FY24 EPS ($1.11) vs. ($1.43) last year
Nuvectis Pharma, Inc. stock logo
Nuvectis Pharma (NVCT) to Release Earnings on Tuesday
Nuvectis Pharma (NASDAQ:NVCT) will be releasing earnings before the market opens on Tuesday, March 4.
Nuvectis Pharma, Inc. stock logo
Insider Buying: Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires 240,000 Shares of Stock
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri bought 240,000 shares of the company's stock in a transaction that occurred on Friday, February 7th. The shares were bought at an average price of $5.00 per share, for a total transaction of $1,200,000.00. Following the acquisition, the insider now directly owns 2,884,121 shares of the company's stock, valued at $14,420,605. This represents a 9.08 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Nuvectis Pharma announces common stock offering, no amount given
Nuvectis Pharma, Inc. stock logo
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Holdings Increased by Baldwin Wealth Partners LLC MA
Baldwin Wealth Partners LLC MA raised its position in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) by 104.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 355,961 shares of the company'
Nuvectis Pharma, Inc. stock logo
Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Buys $20,925.00 in Stock
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) CEO Ron Bentsur bought 4,500 shares of the company's stock in a transaction on Tuesday, December 24th. The stock was bought at an average cost of $4.65 per share, for a total transaction of $20,925.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,270,924 shares of the company's stock, valued at approximately $15,209,796.60. This represents a 0.14 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Nuvectis Pharma, Inc. stock logo
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Acquires $79,900.00 in Stock
Nuvectis Pharma, Inc. (NASDAQ:NVCT - Get Free Report) major shareholder Marlio Charles Mosseri acquired 17,000 shares of the company's stock in a transaction on Friday, December 13th. The shares were purchased at an average cost of $4.70 per share, with a total value of $79,900.00. Following the completion of the purchase, the insider now directly owns 2,612,000 shares of the company's stock, valued at $12,276,400. This trade represents a 0.66 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.
Nuvectis Pharma Share Price (NVCT.US)
Get Nuvectis Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter.

NVCT Media Mentions By Week

NVCT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NVCT
News Sentiment

0.36

0.73

Average
Medical
News Sentiment

NVCT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NVCT Articles
This Week

7

1

NVCT Articles
Average Week

Get Nuvectis Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:NVCT) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners